Amanote Research
Register
Sign In
Human Medicines European Public Assessment Report (EPAR): Arzerra, Ofatumumab, Leukemia, Lymphocytic, Chronic, B-Cell, Date of Authorisation: 19/04/2010, Revision: 16, Status: Withdrawn
Case Medical Research
doi 10.31525/cmr-1250c3e
Full Text
Open PDF
Abstract
Available in
full text
Date
May 10, 2019
Authors
Unknown
Publisher
Case Journals
Related search
Human Medicines European Public Assessment Report (EPAR): Imbruvica, Ibrutinib, Lymphoma, Mantle-Cell,Leukemia, Lymphocytic, Chronic, B-Cell, Date of Authorisation: 21/10/2014, Revision: 13, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Raloxifene Teva, Raloxifene, Osteoporosis, Postmenopausal, Date of Authorisation: 29/04/2010, Revision: 8, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): PritorPlus, Telmisartan / Hydrochlorothiazide, Hypertension, Date of Authorisation: 22/04/2002, Revision: 33, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Bronchitol, Mannitol, Cystic Fibrosis, Date of Authorisation: 13/04/2012, Revision: 13, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Ristfor, Sitagliptin / Metformin Hydrochloride, Diabetes Mellitus, Type 2, Date of Authorisation: 15/03/2010, Revision: 19, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Palonosetron Hospira, Palonosetron, Nausea,Vomiting,Cancer, Date of Authorisation: 08/04/2016, Revision: 4, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Pregabalin Pfizer, Pregabalin, Anxiety Disorders,Epilepsy, Date of Authorisation: 10/04/2014, Revision: 13, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): DuoResp Spiromax, Budesonide / Formoterol, Pulmonary Disease, Chronic Obstructive,Asthma, Date of Authorisation: 28/04/2014, Revision: 7, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Erivedge, Vismodegib, Carcinoma, Basal Cell, Date of Authorisation: 12/07/2013, Date of Refusal: 26/04/2013, Revision: 11, Status: Authorised
Case Medical Research
